Lucid Diligence Brief: SELLAS REGAL AML Phase 3 Nears Final Analysis
Lucid Diligence Brief: SELLAS approaches REGAL AML final analysis for…
Lucid Diligence Brief: Incyte and Genesis Expand Molecular AI Collaboration to Accelerate Drug Discovery
Lucid Diligence Brief: Incyte and Genesis Molecular AI expand collaboration…
Lucid Diligence Brief: Cullinan Therapeutics Gains FDA Orphan Drug Designation for CLN-049
Lucid Diligence Brief: Cullinan Therapeutics Receives FDA Orphan Drug…
Lucid Diligence Brief: Regeneron collaboration with Parabilis Medicines
Lucid Diligence Brief: Regeneron collaboration with Parabilis Medicines…
Vaccines Today—May 8, 2026
This weekly update in vaccines and immunotherapy covers recent developments…
Public Health Today—May 8, 2026
This weekly update in public health and biomedicine highlights emerging…
Public Health Today—May 1, 2026
This is a weekly update in public health, highlighting advances across clinical…
Lucid Diligence Brief: Huahui Health x BeOne Medicines $2 billion collaboration for cancer trispecific HH160
Lucid Diligence Brief: Huahui Health x BeOne Medicines $2 billion collaboration…
Lucid Diligence Brief: Lilly to acquire Ajax Therapeutics
Lucid Diligence Brief: Lilly to acquire Ajax Therapeutics Professional…
Lucid Diligence Brief: Cantargia nadunolimab in MDS and AML
Lucid Diligence Brief: Cantargia nadunolimab in MDS and AML Professional…
In Vivo CAR-T: Stress-Testing the Lilly–Kelonia Deal with AI-Powered Wargaming
Why the Lilly–Kelonia Deal Matters for In Vivo CAR-T Download the…
Lucid Diligence Brief: Eli Lilly acquires Kelonia for up to $7 billion in cash
Lucid Diligence Brief: Eli Lilly acquires Kelonia for up to $7 billion in cash…